Pfizer’s Failed Blood Cancer Drug Shows New Benefits in Study

[guest]

Pfizer Inc.'s blood-cancer drug Mylotarg, pulled from the market last year after it was linked to deaths, helped a different group of patients, a study found.


More...

Toggle signature
||||| Mentor Group Access Now! |||||